These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 3553878)

  • 1. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1989; 19(6):415-21. PubMed ID: 2690730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 7. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy: problems and practices.
    Muenter MD
    Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of administration of low doses of bromocriptine and levodopa in the early treatment of Parkinson disease].
    Sternić N; Kostić V
    Srp Arh Celok Lek; 1992; 120(1-2):1-5. PubMed ID: 1641693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
    Montastruc JL; Rascol O; Rascol A
    Rev Neurol (Paris); 1990; 146(2):144-7. PubMed ID: 2181588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of bromocriptine in the treatment of Parkinson's disease.
    Mackenzie RA; Lance JW
    Clin Exp Neurol; 1978; 15():228-36. PubMed ID: 386307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease.
    Gron U
    Acta Neurol Scand; 1977 Sep; 56(3):269-73. PubMed ID: 333855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
    Hely MA; Morris JG; Reid WG; O'Sullivan DJ; Williamson PM; Rail D; Broe GA; Margrie S
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):903-10. PubMed ID: 8057111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine: long-term low-dose therapy in Parkinson's disease.
    Teychenne PF; Bergsrud D; Elton RL; Racy A
    Clin Neuropharmacol; 1986; 9(2):138-45. PubMed ID: 3708599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
    Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1988; 28 Suppl 1():3-8. PubMed ID: 3378560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.
    Hely MA; Morris JG; Rail D; Reid WG; O'Sullivan DJ; Williamson PM; Genge S; Broe GA
    J Neurol Neurosurg Psychiatry; 1989 Mar; 52(3):324-8. PubMed ID: 2647907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.